Seamus Fernandez
Stock Analyst at Guggenheim
(4.92)
# 31
Out of 5,072 analysts
113
Total ratings
68.35%
Success rate
70.28%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Maintains: Buy | $13 → $11 | $4.60 | +139.13% | 1 | Nov 18, 2025 | |
| CDTX Cidara Therapeutics | Downgrades: Neutral | n/a | $219.75 | - | 6 | Nov 18, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $84 → $77 | $33.82 | +127.68% | 4 | Nov 10, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $6.80 | - | 4 | Oct 23, 2025 | |
| LLY Eli Lilly and Company | Reiterates: Buy | $948 | $1,104.34 | -14.16% | 20 | Oct 16, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $15.00 | +66.67% | 2 | Sep 15, 2025 | |
| TENX Tenax Therapeutics | Maintains: Buy | $15 → $14 | $9.47 | +47.84% | 2 | Aug 14, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $92 → $90 | $34.22 | +163.00% | 2 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $119 → $120 | $107.42 | +11.71% | 2 | Aug 6, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $70.39 | +64.80% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $30.96 | - | 3 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $49.65 | +222.26% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $43.36 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $104.63 | +16.60% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.02 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.17 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $49.25 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.71 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $130.44 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.83 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.88 | +1,775.00% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $26.79 | +67.97% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $93.32 | -59.28% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $25.71 | +47.80% | 3 | Jan 31, 2018 |
Inventiva
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $4.60
Upside: +139.13%
Cidara Therapeutics
Nov 18, 2025
Downgrades: Neutral
Price Target: n/a
Current: $219.75
Upside: -
MBX Biosciences
Nov 10, 2025
Maintains: Buy
Price Target: $84 → $77
Current: $33.82
Upside: +127.68%
Arcturus Therapeutics Holdings
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $6.80
Upside: -
Eli Lilly and Company
Oct 16, 2025
Reiterates: Buy
Price Target: $948
Current: $1,104.34
Upside: -14.16%
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $15.00
Upside: +66.67%
Tenax Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $9.47
Upside: +47.84%
Structure Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $34.22
Upside: +163.00%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $119 → $120
Current: $107.42
Upside: +11.71%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $70.39
Upside: +64.80%
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $30.96
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $49.65
Upside: +222.26%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $43.36
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $104.63
Upside: +16.60%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $48.02
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.17
Upside: -
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $49.25
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $48.71
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $130.44
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.83
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.88
Upside: +1,775.00%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $26.79
Upside: +67.97%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $93.32
Upside: -59.28%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $25.71
Upside: +47.80%